>
Switch to:

Fate Therapeutics EV-to-EBITDA

: -26.09 (As of Today)
View and export this data going back to 2013. Start your Free Trial

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Fate Therapeutics's enterprise value is $5,243.98 Mil. Fate Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2021 was $-201.03 Mil. Therefore, Fate Therapeutics's EV-to-EBITDA for today is -26.09.

The historical rank and industry rank for Fate Therapeutics's EV-to-EBITDA or its related term are showing as below:

NAS:FATE' s EV-to-EBITDA Range Over the Past 10 Years
Min: -56.89   Med: -4.9   Max: 0.08
Current: -25.53

-56.89
0.08

During the past 10 years, the highest EV-to-EBITDA of Fate Therapeutics was 0.08. The lowest was -56.89. And the median was -4.90.

NAS:FATE's EV-to-EBITDA is ranked lower than
99.99% of the 37 Companies
in the Biotechnology industry.

( Industry Median: 17.53 vs. NAS:FATE: -25.53 )

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2021-10-19), Fate Therapeutics's stock price is $60.12. Fate Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2021 was $. Therefore, Fate Therapeutics's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Fate Therapeutics EV-to-EBITDA Historical Data

The historical data trend for Fate Therapeutics's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fate Therapeutics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
EV-to-EBITDA
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.73 -5.79 -10.11 -13.67 -44.57

Fate Therapeutics Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
EV-to-EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -22.06 -20.94 -44.57 -38.51 -37.79

Competitive Comparison

For the Biotechnology subindustry, Fate Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Fate Therapeutics EV-to-EBITDA Distribution

For the Biotechnology industry and Healthcare sector, Fate Therapeutics's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Fate Therapeutics's EV-to-EBITDA falls into.



Fate Therapeutics EV-to-EBITDA Calculation

Fate Therapeutics's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=5243.982/-201.025
=-26.09

Fate Therapeutics's current Enterprise Value is $5,243.98 Mil.
Fate Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-201.03 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fate Therapeutics  (NAS:FATE) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Fate Therapeutics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=60.12/-2.350
=At Loss

Fate Therapeutics's share price for today is $60.12.
Fate Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Fate Therapeutics EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Fate Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Fate Therapeutics Business Description

Fate Therapeutics logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2836
Traded in Other Exchanges
Address
3535 General Atomics Court, Suite 200, San Diego, CA, USA, 92121
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and immune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Executives
Tahl Cindy officer: General Counsel and Secretary C/O FATE THERAPEUTICS, INC. 3535 GENERAL ATOMICS COURT, STE 200 SAN DIEGO CA 92121
Shoemaker Daniel D officer: Chief Scientific Officer C/O FATE THERAPEUTICS, INC. 3535 GENERAL ATOMICS COURT, SUITE 200 SAN DIEGO CA 92121
Valamehr Bahram officer: Chief Development Officer C/O FATE THERAPEUTICS, INC. 3535 GENERAL ATOMICS COURT, STE 200 SAN DIEGO CA 92121
Dulac Edward J Iii officer: Chief Financial Officer FATE THERAPEUTICS, INC. 3535 GENERAL ATOMICS COURT STE 200 SAN DIEGO CA 92121
Redmile Group, Llc director, 10 percent owner ONE LETTERMAN DRIVE BUILDING D, SUITE D3-300 SAN FRANCISCO CA 94129
Green Jeremy director, 10 percent owner ONE LETTERMAN DRIVE, BUILDING D SUITE D3-300 SAN FRANCISCO CA 94129
Jooss Karin director C/O GRITSTONE ONCOLOGY, INC. 5858 HORTON STREET, SUITE 210 EMERYVILLE CA 94608
Agarwal Shefali director C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE CAMBRIDGE MA 02139
Mendlein John director PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: MENDLEIN JOHN a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Rastetter William H director 9885 TOWNE CENTRE DR. SAN DIEGO CA 92121
Hershberg Robert director 3005 FIRST AVENUE SEATTLE WA 98121
Coughlin Timothy director 339 NORTH GRANADOS AVE SOLANA BEACH CA 92075
Lee Michael Stewart director C/O REDMILE GROUP, LLC ONE LETTERMAN DR., BLDG. D, SUITE D3-300 SAN FRANCISCO CA 94129
Epstein Robert S director PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: EPSTEIN ROBERT S a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Wolchko J Scott director, officer: President and CEO C/O FATE THERAPEUTICS, INC. 3535 GENERAL ATOMICS COURT, SUITE 200 SAN DIEGO CA 92121

Fate Therapeutics Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)